Anti-Diabetic Drugs & Cancer Risk Challenge
نویسندگان
چکیده
منابع مشابه
Anti-Diabetic Drugs
Diabetes mellitus affects up to 6% of the UK population, although it is estimated that around half of these individuals remain undiagnosed. It occurs equally in both sexes but varies with age and race. The ethnic group at highest risk is the Pima Indians in North America with a 50% prevalence of diabetes. Other high-risk groups include the Afro-Caribbean and Asian populations, who are at four t...
متن کاملRisk-Benefit Profile of Novel Anti-diabetic Drugs: Current Perspectives
We are facing a paradigm shift in the era of antidiabetics, because agents marketed after 2008 (i.e., after the rosiglitazone saga) are not only required to reduce levels of HbA1, but also to demonstrate beneficial or at least neutral effect with regard to cardiovascular (CV) outcomes (Figure 1). This is of paramount relevance, considering that the risk of developing CV disease is two-fold high...
متن کاملProspective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
Type 2 diabetes mellitus (T2DM) has consistently been associated with decreased risk of prostate cancer; however, if this decrease is related to the use of anti-diabetic drugs is unknown. We prospectively studied men in the comparison cohort in the Prostate Cancer data Base Sweden 3.0, with data on T2DM, use of metformin, sulfonylurea and insulin retrieved from national health care registers an...
متن کاملCardiovascular safety of anti-diabetic drugs.
Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing anti-diabetic drugs that do not increase cardiovascular risk but might reduce the risk of cardiovascular events. Most type 2 diabetic patients die from cardiovascular causes despite the beneficial effects of blood pressure (BP) and lipid-lowering medicatio...
متن کاملMedicinal Chemistry of Novel Anti-Diabetic Drugs
Diabetes mellitus is a common metabolic disorder affecting millions of people worldwide. The prevalence of this chronic, endocrine condition continues to grow, from a world-wide prevalence of 221 million in 2010 to a projected 300 million in 2030 [1, 2]. The majority (~90%) of patients suffering from diabetes mellitus have type 2 while about 10% have type 1. Type 1 diabetes is caused by immunol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes & its Complications
سال: 2019
ISSN: 2639-9326
DOI: 10.33425/2639-9326.1053